Загрузка...
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis
BACKGROUND: Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHuEPO use in predialysis patients which may accelerate the deterio...
Сохранить в:
| Опубликовано в: : | Cochrane Database Syst Rev |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2016
|
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7144724/ https://ncbi.nlm.nih.gov/pubmed/26790135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD003266.pub3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|